| Name | Title | Contact Details |
|---|
Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. As The Imaging Phenomics Company®, Median provides insights into novel therapies and treatment strategies. Our unique solutions, MediScan® for lesion management in patient care, Lesion Management Solution (LMS) for lesion detection, measurement and reporting in clinical trials, and our imaging phenotyping system iBiopsy®, together with our global team of experts, are advancing the development of new drugs and diagnostic tools to monitor disease and assess response to therapy. Median Technologies supports biopharmaceutical sponsors and healthcare professionals around the world in bringing new and targeted treatments to patients in need with an eye on reducing overall costs. This is how we are helping to create a healthier world. Founded in 2002, based in Sophia-Antipolis, France, with a US subsidiary in Boston, Median has received the label “Innovative company” by the BPI and is listed on Euronext Paris` Alternext market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA-PME SME equity savings plan setup and has received the label Pass French Tech Promotion 2016-2017.
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace.
Biohit is a Neptune, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Equipoise Dental Laboratory is a Bergenfield, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Osiris Therapeutics, Inc. is a leading stem cell company focused on developing and marketing products to treat medical conditions in the inflammatory, autoimmune, orthopedic and cardiovascular areas. Osiris’ stem cell products have significant therapeutic potential because of their ability to regulate inflammation, promote tissue regeneration and prevent pathological scar formation. In Biosurgery, we harness the ability of cells and novel constructs to promote the body`s natural healing. The goals are to improve surgical outcomes and offer better treatment options for patients and physicians. We like a challenge, so the focus is in areas where we believe we can have a significant impact. Difficult indications and challenging cases are targeted. Osiris has been studying tissue engineering since the beginning, and its dedicated team conducted groundbreaking research in the field. The work in bone led to the development of the successful product Osteocel, now owned by NuVasive Inc. Now, application of these technologies is being expanded beyond bone, to soft tissues, such as cartilage and tendon, and also wound healing.